市場調査レポート

商品コード

1439210

感染症診断の世界市場の評価：製品タイプ別、サンプルタイプ別、設定別、検査タイプ別、適応症別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Infectious Disease Diagnostics Market Assessment, By Product, By Sample Type, By Setting, By Type of Testing, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年02月28日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 225 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,150円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,190円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,284,940円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.70円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の感染症診断の市場規模は、予測期間中にCAGR 6.17％で成長し、2023年の277億8,000万米ドルから、2031年には448億5,000万米ドルに成長すると予測されています。

感染症診断の市場は、感染症の流行拡大、多様な診断検査のアベイラビリティ、ポイントオブケア診断検査技術への嗜好の高まりといった要因の影響を受けて成長すると予想されています。主要企業による革新的な疾病診断およびモニタリング技術の市場開発も同市場の拡大に大きく寄与しています。また、疾患モデル分析の改善のための投資の増加や、主要企業の戦略的活動も市場成長に寄与しています。

感染症の流行拡大

感染症は21世紀に入ってから増加の一途をたどっており、COVID-19、SARS、豚インフルエンザなどの流行は、世界的に人命と生活に壊滅的な影響を及ぼしています。感染症の流行拡大は、感染症診断ソリューションの需要と正比例しており、市場をさらに拡大させています。感染症は世界の主要な死因の一つであり、効率的な診断によって適切な治療計画が効果的に活用されます。

多様な診断検査のアベイラビリティ

臨床検査、迅速診断検査、血清学的検査、ポリメラーゼ連鎖反応 (PCR) 検査など、感染症には多様な診断検査が利用できます。これらの検査では、抗体、抗原、特定の微生物を検出し、感染症の診断に役立てることができます。臨床検査では、血液、尿、喀痰、その他の体液のサンプルを用いて、染色、培養、分子生物学的手法により微生物を同定します。迅速診断検査は、さまざまな形式やプラットフォームで提供されており、臨床的な意思決定に役立つ迅速な結果を提供し、ポイントオブケアでの管理を可能にします。血清学的検査は、過去に暴露されたことを確認するために抗体を調べ、PCR検査は微生物の遺伝物質を検出します。これらの多様な検査法は、感染症の正確でタイムリーな診断に重要な役割を果たしています。

アジア太平洋がもっとも急成長する地域

アジア太平洋地域では感染症の発生が増加しています。これは、貧困、人口過剰、不十分な予防医療システム、人口増加などの要因によるものです。この地域は新興感染症のホットスポットであり、コレラやデング熱の新型が報告されています。保健・医療インフラの目覚ましい改善にもかかわらず、感染症は依然としてこの地域の主要な死因であり、特に気候的・経済的理由から東南アジアの感染症蔓延率が高くなっています。

当レポートでは、世界の感染症診断の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
製品別
- 試薬・キット・消耗品
- 機器
- ソフトウェア
サンプルタイプ別
- 血液・血液成分
- 尿
- その他
設定別
- 臨床検査
- ポイントオブケア検査
検査タイプ別
- 分子検査
- 血清学的検査
- 抗原検査
- 培養試験
- 血液検査
- 画像検査
適応症別
- 細菌感染症
- ウイルス感染症
- 中枢神経系感染症
- 心血管感染症
- 真菌感染症
- 消化管感染症
- 性感染症
- その他
エンドユーザー別
- 診断ラボ
- 学術機関・医療機関
- 病院
- 外来診療所
- 在宅医療
- その他
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界の感染症診断市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

製品別
サンプルタイプ別
設定別
検査タイプ別
適応症別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/最新技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Becton Dickinson & Company
Cepheid Inc.
Abbott Laboratories
BioMerieux SA
Hologic Inc.
Bio-Rad Laboratories Inc.
Danaher Corporation
Thermo Fisher Scientific Inc.
DiaSorin SpA
F. Hoffmann-La Roche AG

第13章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 4. Global Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 5. Global Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 6. Global Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 7. Global Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 8. Global Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 9. Global Infectious Disease Diagnostics Market Share (%), By Region, 2017-2031F
Figure 10. North America Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 11. North America Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 12. North America Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 13. North America Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 14. North America Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 15. North America Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 16. North America Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 17. North America Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 18. North America Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
Figure 19. United States Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 20. United States Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 21. United States Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 22. United States Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 23. United States Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 24. United States Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 25. United States Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 26. United States Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 27. Canada Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 28. Canada Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 29. Canada Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 30. Canada Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 31. Canada Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 32. Canada Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 33. Canada Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 34. Canada Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 35. Mexico Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 36. Mexico Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 37. Mexico Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 38. Mexico Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 39. Mexico Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 40. Mexico Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 41. Mexico Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 42. Mexico Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 43. Europe Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 44. Europe Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 45. Europe Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 46. Europe Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 47. Europe Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 48. Europe Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 49. Europe Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 50. Europe Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 51. Europe Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
Figure 52. Germany Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 53. Germany Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 54. Germany Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 55. Germany Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 56. Germany Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 57. Germany Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 58. Germany Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 59. Germany Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 60. France Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 61. France Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 62. France Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 63. France Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 64. France Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 65. France Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 66. France Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 67. France Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 68. Italy Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 69. Italy Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 70. Italy Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 71. Italy Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 72. Italy Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 73. Italy Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 74. Italy Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 75. Italy Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 76. United Kingdom Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 77. United Kingdom Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 78. United Kingdom Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 79. United Kingdom Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 80. United Kingdom Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 81. United Kingdom Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 82. United Kingdom Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 83. United Kingdom Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 84. Russia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 85. Russia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 86. Russia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 87. Russia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 88. Russia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 89. Russia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 90. Russia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 91.
Figure 92. Russia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 93. Netherlands Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 94. Netherlands Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 95. Netherlands Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 96. Netherlands Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 97. Netherlands Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 98. Netherlands Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 99. Netherlands Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 100. Netherlands Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 101. Spain Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 102. Spain Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 103. Spain Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 104. Spain Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 105. Spain Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 106. Spain Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 107. Spain Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 108. Spain Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 109. Turkey Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 110. Turkey Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 111. Turkey Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 112. Turkey Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 113. Turkey Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 114. Turkey Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 115. Turkey Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 116. Turkey Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 117. Poland Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 118. Poland Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 119. Poland Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 120. Poland Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 121. Poland Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 122. Poland Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 123. Poland Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 124. Poland Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 125. South America Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 126. South America Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 127. South America Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 128. South America Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 129. South America Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 130. South America Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 131. South America Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 132. South America Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 133. South America Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
Figure 134. Brazil Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 135. Brazil Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 136. Brazil Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 137. Brazil Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 138. Brazil Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 139. Brazil Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 140. Brazil Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 141. Brazil Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 142. Argentina Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 143. Argentina Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 144. Argentina Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 145. Argentina Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 146. Argentina Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 147. Argentina Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 148. Argentina Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 149. Argentina Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 150. Asia-Pacific Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 151. Asia-Pacific Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 152. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 153. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 154. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 155. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 156. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 157. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 158. Asia-Pacific Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
Figure 159. India Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 160. India Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 161. India Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 162. India Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 163. India Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 164. India Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 165. India Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 166. India Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 167. China Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 168. China Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 169. China Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 170. China Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 171. China Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 172. China Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 173. China Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 174. China Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 175. Japan Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 176. Japan Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 177. Japan Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 178. Japan Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 179. Japan Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 180. Japan Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 181. Japan Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 182. Japan Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 183. Australia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 184. Australia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 185. Australia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 186. Australia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 187. Australia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 188. Australia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 189. Australia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 190. Australia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 191. Vietnam Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 192. Vietnam Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 193. Vietnam Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 194. Vietnam Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 195. Vietnam Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 196. Vietnam Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 197. Vietnam Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 198. Vietnam Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 199. South Korea Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 200. South Korea Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 201. South Korea Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 202. South Korea Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 203. South Korea Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 204. South Korea Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 205. South Korea Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 206. South Korea Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 207. Indonesia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 208. Indonesia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 209. Indonesia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 210. Indonesia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 211. Indonesia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 212. Indonesia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 213. Indonesia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 214. Indonesia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 215. Philippines Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 216. Philippines Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 217. Philippines Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 218. Philippines Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 219. Philippines Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 220. Philippines Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 221. Philippines Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 222. Philippines Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 223. Middle East & Africa Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 224. Middle East & Africa Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 225. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 226. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 227. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 228. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 229. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 230. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 231. Middle East & Africa Infectious Disease Diagnostics Market Share (%), By Country, 2017-2031F
Figure 232. Saudi Arabia Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 233. Saudi Arabia Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 234. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 235. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 236. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 237. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 238. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 239. Saudi Arabia Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 240. UAE Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 241. UAE Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 242. UAE Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 243. UAE Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 244. UAE Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 245. UAE Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 246. UAE Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 247. UAE Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 248. South Africa Infectious Disease Diagnostics Market, By Value, In USD Billion, 2017-2031F
Figure 249. South Africa Infectious Disease Diagnostics Market, By Volume, In Million Units, 2017-2031F
Figure 250. South Africa Infectious Disease Diagnostics Market Share (%), By Product, 2017-2031F
Figure 251. South Africa Infectious Disease Diagnostics Market Share (%), By Sample Type, 2017-2031F
Figure 252. South Africa Infectious Disease Diagnostics Market Share (%), By Setting, 2017-2031F
Figure 253. South Africa Infectious Disease Diagnostics Market Share (%), By Type of Testing, 2017-2031F
Figure 254. South Africa Infectious Disease Diagnostics Market Share (%), By Indication, 2017-2031F
Figure 255. South Africa Infectious Disease Diagnostics Market Share (%), By End-user, 2017-2031F
Figure 256. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 257. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 258. By Setting Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 259. By Type of Testing Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 260. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 261. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11046

Global infectious disease diagnostics market is projected to witness a CAGR of 6.17% during the forecast period 2024-2031, growing from USD 27.78 billion in 2023 to USD 44.85 billion in 2031F. Infectious disease diagnostics involve the identification of the causative agent of an infectious disease, such as bacteria, viruses, fungi, or parasites, in a patient with a compatible clinical illness. The process is essential for determining the most effective treatment. Diagnostic methods include laboratory tests, such as blood, urine, and tissue samples, as well as imaging scans to reveal evidence of the microbe causing the disease. The detection of the pathogen can be done through cultivation, isolation in cell culture, and identification biochemically, antigenically, or genetically. Additionally, specific immune responses and molecular technologies are used for accurate diagnosis, especially in low-resource settings.

The infectious disease diagnostics market is expected to thrive under the influence of factors like growing prevalence of infectious diseases, availability of a diverse range of diagnostic tests, and the increasing preference for point-of-care diagnostic testing techniques. The development of innovative disease diagnosis and monitoring technologies by key players in the industry is greatly contributing to the expansion of the market. Increasing investments for improving disease model analysis, and the strategic activities of key players is also contributing to the market growth.

However, the growth of infectious disease diagnostics market may be hindered by a lack of awareness of novel diagnostic solutions, absence of compiled regulatory guidelines, and lower positivity rates due to inferior laboratory conditions. Market players are actively involved in strategic product launches and business tactics to expand the market.

In February 2023, Thermo Fisher Scientific recently announced the release of Applied Biosystems TaqPath PCR kits designed specifically for diagnosing infectious diseases. These kits are effective in detecting diseases such as Multi-Drug Resistant Tuberculosis (MDR-TB), M. Tuberculosis complex (MTB), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV). Moreover, they can be used for genetic analysis (HLA B27). The Central Drugs Standard Control Organization (CDSCO) has approved these kits, and they will be produced in India in partnership with Mylab Discovery Solutions, a leading healthcare company.

Growing Prevalence of Infectious Diseases

Infectious diseases have been on the rise in the 21st century, with outbreaks such as COVID-19, SARS, and swine flu with a devastating impact on lives and livelihoods globally. Factors contributing to the emergence and spread of infectious diseases include ecological, environmental, or demographic factors that place people in increased contact with a previously unfamiliar microbe, as well as increasing prevalence of these factors. The growing prevalence of infectious diseases is directly proportional to the demand for infectious disease diagnostic solutions, further expanding the market. Infectious diseases are one of the leading causes of death globally and a suitable treatment plan be effectively utilized through efficient diagnostics.

According to the World Economic Forum, annually, infectious diseases, such as malaria, HIV, and tuberculosis, are the cause of death for over 2.8 million people, and more than 1.7 billion people require treatment for at least one neglected tropical disease, globally. In addition, epidemic-prone infectious diseases such as COVID-19 and Ebola are anticipated to claim thousands to millions of lives before control and preventive measures can be effective.

Availability of a Diverse Range of Diagnostic Tests

A diverse range of diagnostic tests is available for infectious diseases, including laboratory tests, rapid diagnostic tests, serological testing, and polymerase chain reaction (PCR) testing. These tests can detect antibodies, antigens, and specific microorganisms to aid in the diagnosis of infectious diseases. Laboratory tests use samples of blood, urine, sputum, or other fluids to identify microorganisms through staining, culturing, or molecular methods. Rapid diagnostic tests, which are available in various formats and platforms, provide rapid results to inform clinical decision-making and enable point-of-care management. Serological testing looks for antibodies to verify previous exposure, while PCR testing detects the genetic material of microorganisms. These diverse testing methods play a crucial role in accurate and timely diagnosis of infectious diseases. The diverse range is anticipated to contribute to the expansion of the market. Market players offer a variety of rapid diagnostic kits for different diseases.

In July 2023, EMPE Diagnostics launched mfloDx MDR-TB test kit for rapid diagnosis of tuberculosis and antibiotic resistance. The mfloDx MDR-TB test kit, developed in Genome Valley, provides clear yes/no results in a fraction of the time compared to traditional methods. It's recognized by the World Health Organization and approved by the Central Drugs Standard Control Organization, poised to change tuberculosis diagnostics globally.

Dominance of Laboratory Testing Segment While Fast Growth for PoC Testing

The laboratory testing segment is expected to lead the market with a larger value share throughout the assessment period due to its widespread application areas and efficacy percentage. Clinical laboratory tests encompass a wide range of services, such as complete blood count, basic metabolic panel, genetic testing, and clinical chemistry. While point-of-care testing is anticipated to grow at a higher CAGR owing to the rising rate of adoption of such technologies in diagnostics and the increasing availability of rapid diagnostics test kits. The growth in point-of-care testing is driven by factors like the increased demand for at-home testing and the development of innovative services, including personalized medication selection and dosing based on genetic testing. Market participants are dedicated to expanding their point-of-care portfolio through the launch of new rapid test kits.

For instance, in June 2023, Agdia, Inc. launched a new rapid and field-deployable RNA-based assay to detect Blueberry scorch virus (BlScV). The test has outperformed all commercially available serological (ELISA) tests and matches the performance of the most well-established PCR methods presently in use. The rapid diagnostic kit is called AmplifyRP XRT for BlScV.

Molecular Tests to Dominate the Market

The molecular tests segment is anticipated to dominate the infectious disease diagnostics market. Molecular diagnostics, including techniques such as DNA microarray analysis, is one of the fastest-growing areas in infectious disease identification. Molecular diagnostics is a modern solution for detecting parasitic, bacterial, and viral infections. Unlike traditional testing methods, these tests are more advanced and overcome the drawbacks of manually prepared media, longer turnaround duration, and poor sensitivity. They are highly accurate and reliable, making them an essential tool in the field of medical diagnosis.

For instance, in November 2023, Roche launched the LightCycler PRO System which uses the reliable technology of the LightCycler Systems that preceded it. The new system offers better performance and is more user-friendly, while bridging the gap between translational research and in-vitro diagnostics. The LightCycler PRO System is a great addition to Roche's molecular PCR testing portfolio, which includes solutions for various healthcare professionals. These solutions cater to those performing research as well as those testing patients for cancer, infectious diseases, and other public health challenges.

Asia-Pacific to be the Fastest Growing Region

Asia-Pacific is experiencing a growing incidence of infectious diseases. It is due to factors such as poverty, overpopulation, inadequate preventive health systems, and increasing population. The region is a hotspot for emerging infectious diseases, with new variants of cholera and dengue being reported. Despite impressive improvements in health and healthcare infrastructure, infectious diseases remain the major cause of death in the region. The share of deaths due to infectious diseases is increasing in the Asia-Pacific. In the region, Southeast Asia has a higher growth rate due to climatic and economic reasons for the widespread of infectious diseases.

According to the 'Health at a Glance: Asia-Pacific 2022' report published by WHO in 2023, Southeast Asia accounted for the largest number of tuberculosis cases globally in 2020, about 43% of the total cases. Among the countries and territories most affected by tuberculosis in 2020 were India (26.0% of tuberculosis cases globally), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), and Bangladesh (3.6%).

Future Market Scenario (2024 - 2031F)

The diagnostic industry is witnessing growing regulatory approvals for infectious disease diagnostic solutions, which are expected to be marketed in near future, further boosting the market. For instance, the Biomedical Advanced Research and Development Authority (BARDA) has supported a diverse portfolio of medical solutions and these products have received a total of 86 FDA approvals, licensures, or clearances. Similarly, the Infectious Diseases Society of America (IDSA) has highlighted the need for new incentives and regulatory changes to spur R&D for new antibiotics and flexible regulations to allow innovative test development to keep pace with emerging infectious diseases. The increasing regulatory approved products for infectious disease diagnosis are anticipated to land the market in future and bring a healthy competition among key players. The FDA has approved a number of diagnostic devices and authorized the emergency use of uncleared devices for infectious diseases, including influenza and respiratory syncytial virus.

In February 2023, The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test. This test is capable of detecting and differentiating influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19. The Lucira COVID-19 & Flu Home Test is a single-use kit that can be used at home. The test provides results from self-collected nasal swab samples in around 30 minutes.

Key Players Landscape and Outlook

These companies have a strong market presence with a vast product portfolio to offer in the field of diagnostics and research. With the growing infectious disease scenario, these players have strengthened their offerings through collaborations, mergers and acquisitions, and other market tactics.

In April 2023, Biosynex SA announced that it had completed its acquisition of Chembio Diagnostics, Inc. The combination of the two companies' technologies and product portfolios, and the combination of market opportunities, will be important growth drivers for the combined entity. Additionally, significant operational synergies are expected in procurement, research and diagnostics logistics, and production.

In July 2023, Novacyt announced its acquisition of Yourgene Health for approximately EUR 16.7 million (USD 21.2 million) in cash. Yourgene Health, located in Manchester, the United Kingdom, offers a range of molecular diagnostic tests for prenatal screening, male infertility, thrombosis risk, and cystic fibrosis. In addition, the company provides genomic medicine services to healthcare, research, and biopharmaceutical clients.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Diagnostics Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Product
- 4.2.1. Reagents, Kits, and Consumables
- 4.2.2. Instruments
- 4.2.3. Software
4.3. By Sample Type
- 4.3.1. Blood and Components
- 4.3.2. Urine
- 4.3.3. Other
4.4. By Setting
- 4.4.1. Laboratory Testing
- 4.4.2. Point-of-Care Testing
4.5. By Type of Testing
- 4.5.1. Molecular Tests
- 4.5.2. Serological Tests
- 4.5.3. Antigen Tests
- 4.5.4. Culture Tests
- 4.5.5. Blood Tests
- 4.5.6. Imaging Tests
4.6. By Indication
- 4.6.1. Bacterial Infections
- 4.6.2. Viral Infections
- 4.6.3. CNS Infections
- 4.6.4. Cardiovascular Infections
- 4.6.5. Fungal Infections
- 4.6.6. GI Infections
- 4.6.7. Sexually Transmitted Diseases
- 4.6.8. Other
4.7. By End-user
- 4.7.1. Diagnostic Laboratories
- 4.7.2. Academic And Medical Institutes
- 4.7.3. Hospitals
- 4.7.4. Ambulatory Clinics
- 4.7.5. Home Healthcare
- 4.7.6. Other
4.8. By Region
- 4.8.1. North America
- 4.8.2. Europe
- 4.8.3. Asia-Pacific
- 4.8.4. South America
- 4.8.5. Middle East and Africa
4.9. By Company Market Share (%), 2023

5. Global Infectious Disease Diagnostics Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Product
  - 5.1.2.1. Reagents, Kits, and Consumables
  - 5.1.2.2. Instruments
  - 5.1.2.3. Software
- 5.1.3. By Sample Type
  - 5.1.3.1. Blood and Components
  - 5.1.3.2. Urine
  - 5.1.3.3. Other
- 5.1.4. By Setting
  - 5.1.4.1. Laboratory Testing
  - 5.1.4.2. Point-of-Care Testing
- 5.1.5. By Type of Testing
  - 5.1.5.1. Molecular Tests
  - 5.1.5.2. Serological Tests
  - 5.1.5.3. Antigen Tests
  - 5.1.5.4. Culture Tests
  - 5.1.5.5. Blood Tests
  - 5.1.5.6. Imaging Tests
- 5.1.6. By Indication
  - 5.1.6.1. Bacterial Infections
  - 5.1.6.2. Viral Infections
  - 5.1.6.3. CNS Infections
  - 5.1.6.4. Cardiovascular Infections
  - 5.1.6.5. Fungal Infections
  - 5.1.6.6. GI Infections
  - 5.1.6.7. Sexually Transmitted Diseases
  - 5.1.6.8. Other
- 5.1.7. By End-user
  - 5.1.7.1. Diagnostic Laboratories
  - 5.1.7.2. Academic And Medical Institutes
  - 5.1.7.3. Hospitals
  - 5.1.7.4. Ambulatory Clinics
  - 5.1.7.5. Home Healthcare
  - 5.1.7.6. Other
- 5.1.8. United States*
  - 5.1.8.1. Market Size & Forecast
  - 5.1.8.1.1. By Value
  - 5.1.8.1.2. By Volume
  - 5.1.8.2. By Product
  - 5.1.8.2.1. Reagents, Kits, and Consumables
  - 5.1.8.2.2. Instruments
  - 5.1.8.2.3. Software
  - 5.1.8.3. By Sample Type
  - 5.1.8.3.1. Blood and Components
  - 5.1.8.3.2. Urine
  - 5.1.8.3.3. Other
  - 5.1.8.4. By Setting
  - 5.1.8.4.1. Laboratory Testing
  - 5.1.8.4.2. Point-of-Care Testing
  - 5.1.8.5. By Type of Testing
  - 5.1.8.5.1. Molecular Tests
  - 5.1.8.5.2. Serological Tests
  - 5.1.8.5.3. Antigen Tests
  - 5.1.8.5.4. Culture Tests
  - 5.1.8.5.5. Blood Tests
  - 5.1.8.5.6. Imaging Tests
  - 5.1.8.6. By Indication
  - 5.1.8.6.1. Bacterial Infections
  - 5.1.8.6.2. Viral Infections
  - 5.1.8.6.3. CNS Infections
  - 5.1.8.6.4. Cardiovascular Infections
  - 5.1.8.6.5. Fungal Infections
  - 5.1.8.6.6. GI Infections
  - 5.1.8.6.7. Sexually Transmitted Diseases
  - 5.1.8.6.8. Other
  - 5.1.8.7. By End-user
  - 5.1.8.7.1. Diagnostic laboratories
  - 5.1.8.7.2. Academic and medical institutes
  - 5.1.8.7.3. Hospitals
  - 5.1.8.7.4. Ambulatory clinics
  - 5.1.8.7.5. Home healthcare
  - 5.1.8.7.6. Other
- 5.1.9. Canada
- 5.1.10. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Product
6.2. By Sample Type
6.3. By Setting
6.4. By Type of Testing
6.5. By Indication
6.6. By End-user
6.7. By Region

7. Macro Environment and Industry Structure

7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.4.7. Supplier Power
- 7.4.8. Buyer Power
- 7.4.9. Substitution Threat
- 7.4.10. Threat from New Entrant
- 7.4.11. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

12.1. Becton Dickinson & Company
- 12.1.1. Company Details
- 12.1.2. Key Management Personnel
- 12.1.3. Products & Services
- 12.1.4. Financials (As reported)
- 12.1.5. Key Market Focus & Geographical Presence
- 12.1.6. Recent Developments
12.2. Cepheid Inc.
12.3. Abbott Laboratories
12.4. BioMerieux SA
12.5. Hologic Inc.
12.6. Bio-Rad Laboratories Inc.
12.7. Danaher Corporation
12.8. Thermo Fisher Scientific Inc.
12.9. DiaSorin SpA
12.10. F. Hoffmann-La Roche AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

感染症診断の世界市場の評価：製品タイプ別、サンプルタイプ別、設定別、検査タイプ別、適応症別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Infectious Disease Diagnostics Market Assessment, By Product, By Sample Type, By Setting, By Type of Testing, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の感染症診断市場の展望

第5章世界の感染症診断市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第13章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Diagnostics Market Outlook, 2017-2031F

5. Global Infectious Disease Diagnostics Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13. Strategic Recommendations

14. About Us & Disclaimer

感染症診断の世界市場の評価：製品タイプ別、サンプルタイプ別、設定別、検査タイプ別、適応症別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Infectious Disease Diagnostics Market Assessment, By Product, By Sample Type, By Setting, By Type of Testing, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の感染症診断市場の展望

第5章 世界の感染症診断市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第13章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Infectious Disease Diagnostics Market Outlook, 2017-2031F

5. Global Infectious Disease Diagnostics Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13. Strategic Recommendations

14. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の感染症診断市場の展望

第5章世界の感染症診断市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第13章戦略的提言

第15章当社について・免責事項